A Computational Study of Natural Compounds from Bacopa monnieri in the Treatment of Alzheimer's Disease.
AChE
AD
Bacopa
BuChE
docking
inhibitors.
Journal
Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
07
2019
revised:
04
09
2019
accepted:
24
09
2019
pubmed:
3
1
2020
medline:
4
11
2020
entrez:
3
1
2020
Statut:
ppublish
Résumé
Keeping in view the public health-related issues of Alzheimer's disease (AD), its unpredictable occurrence and progression indicate the needs for best treatment options. The present bioinformatics study explores the binding pattern and molecular interactions between human acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes with natural compounds from Bacopa monnieri. The docking analysis between natural compounds as a ligand and AChE, BuChE as a receptor was completed using MGL tools Autodock 4.2 module. The analysis of the hydrophobic interactions, inhibition constants, and hydrogen bonds may indicates that they play a significant role in finding out the interacting position at the active site. However, after analyzing the binding energy (ΔG), the documented data shows that bacoside X, bacoside A, 3-beta-D-glucosylstigmasterol and daucosterol could be good inhibitors in the inhibition of AChE and BuChE activities. Therefore, our study indicates that the inhibition constants of the aforesaid natural compounds of Bacopa can be utilized for the development of inhibitors.
Identifiants
pubmed: 31894743
pii: CPD-EPUB-103427
doi: 10.2174/1381612826666200102142257
doi:
Substances chimiques
Cholinesterase Inhibitors
0
Phytochemicals
0
Acetylcholinesterase
EC 3.1.1.7
Butyrylcholinesterase
EC 3.1.1.8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
790-800Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.